Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice.
Br J Cancer
; 124(8): 1346-1352, 2021 04.
Article
in En
| MEDLINE
| ID: mdl-33589773
Full text:
1
Database:
MEDLINE
Main subject:
Breast Neoplasms
/
Biosimilar Pharmaceuticals
/
Trastuzumab
Limits:
Female
/
Humans
Language:
En
Journal:
Br J Cancer
Year:
2021
Type:
Article
Affiliation country:
Germany